Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients (2020)
- Authors:
- USP affiliated authors: GOUVEIA, GISELE RODRIGUES - FM ; PEREIRA, JULIANA - FM
- Unidade: FM
- DOI: 10.1186/s12885-020-07553-2
- Subjects: ENVELHECIMENTO; BIOMARCADORES; MEIA IDADE; ESTUDOS RETROSPECTIVOS; TAXA DE SOBREVIVÊNCIA; LINFOMA
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Bmc cancer
- ISSN: 1471-2407
- Volume/Número/Paginação/Ano: v. 20, n. 1, article ID 1041, 9p, 2020
- Este periódico é de acesso aberto
- Este artigo é de acesso aberto
- URL de acesso aberto
- Cor do Acesso Aberto: gold
- Licença: cc-by
-
ABNT
GOUVEIA, Gisele Rodrigues et al. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients. Bmc cancer, v. 20, n. 1, 2020Tradução . . Disponível em: https://doi.org/10.1186/s12885-020-07553-2. Acesso em: 31 dez. 2025. -
APA
Gouveia, G. R., Ferreira, S. C., Siqueira, S. A. C., Lage, L. A. de P. C., Hallack Neto, A. E., Costa, R. de O., & Pereira, J. (2020). Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients. Bmc cancer, 20( 1). doi:10.1186/s12885-020-07553-2 -
NLM
Gouveia GR, Ferreira SC, Siqueira SAC, Lage LA de PC, Hallack Neto AE, Costa R de O, Pereira J. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients [Internet]. Bmc cancer. 2020 ; 20( 1):[citado 2025 dez. 31 ] Available from: https://doi.org/10.1186/s12885-020-07553-2 -
Vancouver
Gouveia GR, Ferreira SC, Siqueira SAC, Lage LA de PC, Hallack Neto AE, Costa R de O, Pereira J. Overexpression of OCT-1 gene is a biomarker of adverse prognosis for diffuse large B-cell lymphoma (DLBCL): data from a retrospective cohort of 77 Brazilian patients [Internet]. Bmc cancer. 2020 ; 20( 1):[citado 2025 dez. 31 ] Available from: https://doi.org/10.1186/s12885-020-07553-2 - Comparison of two methods of RNA extraction from formalin-fixed paraffin-embedded tissue specimens
- Expression of CysLTR1 and 2 in Maturating Lymphocytes of Hyperplasic Tonsils Compared to Peripheral Cells in Children
- Macrophage migration inhibitory factor and chemokine RANTES in young pediatric patients with congenital cardiac communications: relation to hemodynamic parameters and the presence of Down syndrome
- CD4+ lymphocytes in asymptomatic HTLV-1 carriers present cell cycle arrest in GO/G1 phase
- Detecção da expressão dos genes associados à resistência múltipla à droga, OCT1 e MDR1 e do gene BCL2 em linfoma difuso de grandes células B
- Time-to-treatment of diffuse large B-cell lymphoma in São Paulo
- Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study
- Immune reconstitution inflammatory syndrome-associated lymphoma: a retrospective Brazilian cohort
- Angioimmunoblastic T-cell lymphoma and correlated neoplasms with T-cell follicular helper phenotype: from molecular mechanisms to therapeutic advances
- Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma
Informações sobre o DOI: 10.1186/s12885-020-07553-2 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
